COSUMO:: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis

Mohammad O. Tallouzi; Jonathan M. Mathers; David J. Moore; Philip I. Murray; Nicholas Bucknall; Jane M. Blazeby; Melanie Calvert; Alastair K. Denniston

doi:10.1186/s13063-017-2294-8

COSUMO: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis

Mohammad O. Tallouzi, Jonathan M. Mathers, David J. Moore, Philip I. Murray, Nicholas Bucknall, Jane M. Blazeby, Melanie Calvert, Alastair K. Denniston

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

231 Downloads (Pure)

Abstract

Uveitis, a group of disorders characterised by intraocular inflammation, causes 10–15% of total blindness in the developed world. The most sight-threatening uveitis affects the posterior segment of the eye (posterior-segment involving uveitis (PSIU)). Numerous different outcomes have been used in clinical trials evaluating alternative treatments for uveitis, limiting inter-trial comparison and aggregation of data. We aim to develop a core outcome set (COS) that would provide a standardised set of outcomes to be measured and reported in all effectiveness trials for PSIU.

Original language	English
Article number	576
Journal	Trials
Volume	18
DOIs	https://doi.org/10.1186/s13063-017-2294-8
Publication status	Published - 1 Dec 2017

Keywords

uveitis
core outcome set
macular oedema
domain
Delphi
interviews
focus group
consensus method
clinical trials
key stakeholders

Access to Document

10.1186/s13063-017-2294-8Licence: Creative Commons: Attribution (CC BY)

Tallouzi_et_al_COSUMO_study_protocol_Trials_2017Final published version, 1.01 MBLicence: Creative Commons: Attribution (CC BY)

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2294-8Licence: Creative Commons: Attribution (CC BY)

Cite this

@article{12747ddf058646c6adf6db16335fa421,

title = "COSUMO:: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis",

abstract = "Uveitis, a group of disorders characterised by intraocular inflammation, causes 10–15% of total blindness in the developed world. The most sight-threatening uveitis affects the posterior segment of the eye (posterior-segment involving uveitis (PSIU)). Numerous different outcomes have been used in clinical trials evaluating alternative treatments for uveitis, limiting inter-trial comparison and aggregation of data. We aim to develop a core outcome set (COS) that would provide a standardised set of outcomes to be measured and reported in all effectiveness trials for PSIU.",

keywords = "uveitis , core outcome set , macular oedema , domain , Delphi , interviews , focus group , consensus method , clinical trials , key stakeholders",

author = "Tallouzi, {Mohammad O.} and Mathers, {Jonathan M.} and Moore, {David J.} and Murray, {Philip I.} and Nicholas Bucknall and Blazeby, {Jane M.} and Melanie Calvert and Denniston, {Alastair K.}",

year = "2017",

month = dec,

day = "1",

doi = "10.1186/s13063-017-2294-8",

language = "English",

volume = "18",

journal = "Trials",

issn = "1745-6215",

publisher = "Springer",

}

TY - JOUR

T1 - COSUMO:

T2 - study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis

AU - Tallouzi, Mohammad O.

AU - Mathers, Jonathan M.

AU - Moore, David J.

AU - Murray, Philip I.

AU - Bucknall, Nicholas

AU - Blazeby, Jane M.

AU - Calvert, Melanie

AU - Denniston, Alastair K.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Uveitis, a group of disorders characterised by intraocular inflammation, causes 10–15% of total blindness in the developed world. The most sight-threatening uveitis affects the posterior segment of the eye (posterior-segment involving uveitis (PSIU)). Numerous different outcomes have been used in clinical trials evaluating alternative treatments for uveitis, limiting inter-trial comparison and aggregation of data. We aim to develop a core outcome set (COS) that would provide a standardised set of outcomes to be measured and reported in all effectiveness trials for PSIU.

AB - Uveitis, a group of disorders characterised by intraocular inflammation, causes 10–15% of total blindness in the developed world. The most sight-threatening uveitis affects the posterior segment of the eye (posterior-segment involving uveitis (PSIU)). Numerous different outcomes have been used in clinical trials evaluating alternative treatments for uveitis, limiting inter-trial comparison and aggregation of data. We aim to develop a core outcome set (COS) that would provide a standardised set of outcomes to be measured and reported in all effectiveness trials for PSIU.

KW - uveitis

KW - core outcome set

KW - macular oedema

KW - domain

KW - Delphi

KW - interviews

KW - focus group

KW - consensus method

KW - clinical trials

KW - key stakeholders

U2 - 10.1186/s13063-017-2294-8

DO - 10.1186/s13063-017-2294-8

M3 - Article

SN - 1745-6215

VL - 18

JO - Trials

JF - Trials

M1 - 576

ER -

COSUMO: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis

Abstract

Keywords

Access to Document

Fingerprint

Cite this